Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

Key Takeaways Bristol Myers' ((BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in the second quarter. BMY Faces Competition for the CAR- T Cell Therapy Breyanzi faces competition from Gilead Sciences' ((GILD) Yescarta for its approved indications. Gilead's Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with LBCL that is refractory to first-line chemoimmunotherapy or relapses within 12 m ...